<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00333437</url>
  </required_header>
  <id_info>
    <org_study_id>CEL371</org_study_id>
    <nct_id>NCT00333437</nct_id>
  </id_info>
  <brief_title>Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement</brief_title>
  <official_title>Pulmonary Involvement in Scleroderma: Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers from the Division of Pulmonary and Critical Care Medicine at University of
      California, San Francisco (UCSF) are conducting a study to evaluate whether mycophenolate
      mofetil (an immunosuppressive medication, trade named CellCept) is safe and effective for
      preventing the lung damage from scleroderma from getting worse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is designed to evaluate the safety and efficacy of mycophenolate mofetil
      (CellCept) for the treatment of symptomatic pulmonary alveolitis due to systemic sclerosis
      (SSc). This study utilizes a prospective, open-label, experimental design.

      Primary Hypothesis: The alveolitis in patients with SSc, as defined by decreased forced vital
      capacity (FVC), bronchoalveolar lavage (BAL), and High Resolution Chest Tomography (HRCT) is
      responsive to 1 year of daily mycophenolate mofetil therapy.

      Secondary Hypothesis: Quality of life, six-minute walk and single-breath diffusing capacity
      for carbon monoxide (DLCO) improve in patients with SSc mediated alveolitis after therapy
      with mycophenolate mofetil. This response to therapy is associated with a change in the
      inflammatory cytokine profile present in BAL fluid.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>compare pre- and post-therapy FVC (post- minus pre-). Forced vital capacity (FVC) is the volume of air (liters) that can forcibly be blown out after full inspiration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Bronchoalveolar Lavage (BAL) Components (Neutrophils, Eosinophils)</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>BAL samples were colleected from the affected lobe (as determined by lung CT scans) before beginning and after completing study therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Shortness of Breath (Self-reported)</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Participants reported frequency of shortness of breath experienced with exertion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Six Minute Walk Distance</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of 6-minute walk distance before beginning and after completing study therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)</measure>
    <time_frame>12 months</time_frame>
    <description>DLCO was measured before beginning and after completion of study therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Scleroderma, Systemic</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mycophenolate Mofetil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To participate in this study, patients must first undergo a BAL and HRCT. To be
             eligible to undergo HRCT and BAL (under the purview of this trial), prospective
             patients must meet the following criteria:

               -  Aged 21-70.

               -  Negative pregnancy test (with a sensitivity of at least 50 mIU/mL) for females of
                  child-bearing potential

               -  All patients must fulfill the criteria for SSc by American College of
                  Rheumatology (ACR) criteria (Subcommittee for Scleroderma Criteria 1980).

               -  FVC &lt; 85% of predicted.

               -  SSc for no more than 7 years with onset defined as the date of the first
                  non-Raynaud manifestation.

               -  Patients may have limited (cutaneous thickening distal but not proximal to elbows
                  and knees, with or without facial involvement) or diffuse (cutaneous thickening
                  proximal to elbows and knees, often involving the chest or abdomen) cutaneous SSc
                  (Medsger 1995).

               -  Abnormal DLCO and abnormalities on the plain chest radiograph are not required,
                  although a normal DLCO would be unusual in the face of significant ventilatory
                  restriction due to SSc lung disease.

          -  To be eligible to take study medication, the patient must meet not only the criteria
             above, but also must have ≥ 3.0% neutrophils or ≥ 2.0% eosinophils in screening BAL
             fluid and/or ground glass opacification on HRCT.

          -  Women of childbearing potential should have a negative serum or urine pregnancy test
             with a sensitivity of at least 50 mIU/mL within 1 week before beginning therapy.
             CellCept therapy will not be initiated until a report of a negative pregnancy test has
             been obtained.

          -  Effective contraception must be used before beginning CellCept therapy, during
             therapy, and for 6 weeks following discontinuation of therapy, even where there has
             been a history of infertility, unless due to hysterectomy. Two reliable forms of
             contraception must be used simultaneously unless abstinence is the chosen method. If
             pregnancy does occur during treatment, the physician and patient should discuss the
             desirability of continuing the pregnancy.

        Exclusion Criteria:

          -  FVC &lt; 45% of predicted or DLCO (corrected for hemoglobin [Hgb] but not for alveolar
             volume) &lt; 35% of predicted (suggestive of severe, probably irreparable, disease).

          -  Leukopenia (white blood cell count &lt; 4000) or thrombocytopenia (platelet count &lt;
             100,000).

          -  Serum creatinine ≥ 2.0 mg/dl.

          -  Pregnancy, breast feeding, unreliability, drug abuse, or chronic debilitating disease.

          -  Uncontrolled congestive heart failure.

          -  Active infection of the lung, or elsewhere, whose management would be compromised by
             mycophenolate mofetil.

          -  Prior treatment for alveolitis with mycophenolate mofetil or prior or current
             treatment for alveolitis with: D-penicillamine, methotrexate, colchicine, Potaba, or
             azathioprine.

          -  Other serious concomitant medical illness (e.g., cancer).

          -  Forced expiratory volume in 1 second (FEV1)/FVC ratio &lt; 65%.

          -  If of childbearing potential, failure regularly to be employing two reliable means of
             contraception (i.e., condom, abstinence, intrauterine device (IUD), tubal ligation,
             vasectomy)

          -  Pulmonary hypertension (defined as an estimated systolic blood pressure (SBP) ≥ 35
             mmHg measured by echocardiogram).

          -  Smoking of cigars, pipes, or cigarettes during the past 6 months.

          -  Clinically significant abnormalities on chest x-ray or HRCT scan other than
             interstitial lung disease (e.g., lung mass, evidence of active pulmonary infection).

          -  Use of prednisone (or equivalent) in doses &gt; 10 mg per day.

          -  Does not have ≥ 3.0% neutrophils or ≥ 2.0% eosinophils on screening BAL fluid and does
             not have ground glass opacification on HRCT.

          -  Unable to take oral medication.

          -  Not able to comply with study procedures in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey A Golden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF, 400 Parnassus Ave</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pulmonary.ucsf.edu/activities/ild.html</url>
    <description>UCSF PULMONARY &amp; CRITICAL CARE MEDICINE, INTERSTITIAL LUNG DISEASE CENTER OF EXCELLENCE</description>
  </link>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2006</study_first_submitted>
  <study_first_submitted_qc>June 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2006</study_first_posted>
  <results_first_submitted>May 6, 2013</results_first_submitted>
  <results_first_submitted_qc>May 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 17, 2013</results_first_posted>
  <last_update_submitted>September 23, 2013</last_update_submitted>
  <last_update_submitted_qc>September 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Scleroderma, Systemic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>8 patients were screened at one clinical site (UCSF) in the United States</recruitment_details>
      <pre_assignment_details>One patient screened for enrollment did not meet eligibility criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Single-group Study Treatment</title>
          <description>Study subjects receive standard mycophenolate dosing 2 grams/day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Study subjects receive standard mycophenolate dosing.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.57" spread="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Forced Vital Capacity (FVC)</title>
        <description>compare pre- and post-therapy FVC (post- minus pre-). Forced vital capacity (FVC) is the volume of air (liters) that can forcibly be blown out after full inspiration.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Study subjects receive standard mycophenolate dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Forced Vital Capacity (FVC)</title>
          <description>compare pre- and post-therapy FVC (post- minus pre-). Forced vital capacity (FVC) is the volume of air (liters) that can forcibly be blown out after full inspiration.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1786" spread="0.1613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>H(0): post-pre FVC (liters) = 0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <p_value_desc>Not adjusted</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Change from Baseline</param_type>
            <param_value>0.1786</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.1613</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0294</ci_lower_limit>
            <ci_upper_limit>0.3277</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Bronchoalveolar Lavage (BAL) Components (Neutrophils, Eosinophils)</title>
        <description>BAL samples were colleected from the affected lobe (as determined by lung CT scans) before beginning and after completing study therapy.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Study subjects receive standard mycophenolate dosing 2 grams/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Bronchoalveolar Lavage (BAL) Components (Neutrophils, Eosinophils)</title>
          <description>BAL samples were colleected from the affected lobe (as determined by lung CT scans) before beginning and after completing study therapy.</description>
          <units>Cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean change in neutrophil count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean change in eosinophil count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>H(0): Post-pre neutrophil count = 0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3652</p_value>
            <p_value_desc>significant p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>8.1035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.49</ci_lower_limit>
            <ci_upper_limit>4.4945</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>H(0): post-pre eosinophil count = 0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3485</p_value>
            <p_value_desc>significant p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.286</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>16.358</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.41</ci_lower_limit>
            <ci_upper_limit>8.8426</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Shortness of Breath (Self-reported)</title>
        <description>Participants reported frequency of shortness of breath experienced with exertion</description>
        <time_frame>Baseline, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Study subjects receive standard mycophenolate dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Shortness of Breath (Self-reported)</title>
          <description>Participants reported frequency of shortness of breath experienced with exertion</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patient-reported less shortness of breath</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient-reported no change in shortness of breath</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient-reported increased shortness of breath</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Six Minute Walk Distance</title>
        <description>Comparison of 6-minute walk distance before beginning and after completing study therapy</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Study subjects receive standard mycophenolate dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Six Minute Walk Distance</title>
          <description>Comparison of 6-minute walk distance before beginning and after completing study therapy</description>
          <units>Feet</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264.3" spread="194.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>H(0): post-pre walk distance = 0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0115</p_value>
            <p_value_desc>Significant p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Not adjusted</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>264.26</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>194.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.256</ci_lower_limit>
            <ci_upper_limit>444.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)</title>
        <description>DLCO was measured before beginning and after completion of study therapy</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Study subjects receive standard mycophenolate dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)</title>
          <description>DLCO was measured before beginning and after completion of study therapy</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>H(0): Post-pre DLCO = 0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0167</p_value>
            <p_value_desc>significant p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.8643</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.5013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4758</ci_lower_limit>
            <ci_upper_limit>3.2527</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>Appropriate safety and serological studies were obtained prior to starting study medication and on a regular basis throughout the study. Patients were asked to keep a diary of significant medical events occurring between visits.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Study subjects receive standard mycophenolate dosing.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <description>Patient was hospitalized</description>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal distress</sub_title>
                <description>Patient was unable to tolerate full dose of study drug because of GI distress</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey A. Golden, MD</name_or_title>
      <organization>University of California San Francisco</organization>
      <phone>415-353-2935</phone>
      <email>Jeff.Golden@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

